Description of Collaborative Activity: |
A monthly meeting to enhance communication between the two agencies, thereby expediting the development of new anti-cancer agents. General topics discussed include patient safety, clinical efficacy, and regulatory pathways to licensure; as well as an understanding of the operations of the sister agencies. |